Develops novel oral small molecule therapeutics for chronic diseases. Focuses on G-protein-coupled receptors (GPCRs) as drug targets. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 59% below its peak. The market has trimmed its expectations for the company.
There is $1.4B in the vault; even if every debt were paid off, $1.4B would remain.
A loss of $141.2M against $0 in annual sales.
The growth engine is running at low revs right now. Report-card grade: 13/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 45/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, GPCR sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: GPCR is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (57/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.